Grufity logo
Grufity logo
AIM

AIM - AIM ImmunoTech Inc Stock Price, Fair Value and News

$0.41+0.02 (+5.13%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

22/100

AIM

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

22/100

AIM

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

AIM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AIM Price Action

Last 7 days

-25%

Last 30 days

56.0%

Last 90 days

-45.1%

Trailing 12 Months

-94%

AIM RSI Chart

AIM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AIM Valuation

Market Cap

3.4M

Price/Earnings (Trailing)

-0.25

Price/Sales (Trailing)

35.87

Price/Free Cashflow

-0.3

AIM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

AIM Fundamentals

AIM Revenue

Revenue (TTM)

94.0K

Rev. Growth (Yr)

37.5%

Rev. Growth (Qtr)

4.76%

AIM Earnings

Earnings (TTM)

-13.3M

Earnings Growth (Yr)

18.41%

Earnings Growth (Qtr)

27.59%

AIM Profitability

Operating Margin

-1559.57%

Return on Equity

-624.75%

Return on Assets

-154.64%

Free Cashflow Yield

-335.58%

AIM Investor Care

Shares Dilution (1Y)

1002.30%

Diluted EPS (TTM)

-3.95

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
202694.0K---
2025146.0K121.0K112.0K88.0K
2024193.0K201.0K190.0K170.0K
2023156.5K168.5K193.5K202.0K
2022139.5K146.5K134.5K140.5K
2021146.0K129.0K126.0K134.5K
2020185.0K196.0K171.0K163.0K
2019-340.0K368.0K380.0K
2018409.0K229.0K177.0K367.0K
2017137.0K335.0K403.0K437.0K
2016136.0K104.0K103.0K92.0K
2015157.0K168.0K146.0K133.0K
2014167.0K184.0K193.0K197.0K
2013197.3K181.5K165.8K150.0K
2012---213.0K
2011-139.0K143.0K146.0K
2010-119.0K127.0K135.0K
2009---111.0K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About AIM ImmunoTech Inc

AIM
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
 CEO
 WEBSITEhttps://aimimmuno.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES22

AIM ImmunoTech Inc Frequently Asked Questions

AIM is the stock ticker symbol of AIM ImmunoTech Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of AIM ImmunoTech Inc is 3.21 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, AIM's PE ratio (Price to Earnings) is -0.24 and Price to Sales (PS) ratio is 34.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AIM PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, AIM ImmunoTech Inc has provided -0.616 (multiply by 100 for percentage) rate of return.